1. Home
  2. RUBI vs SHPH Comparison

RUBI vs SHPH Comparison

Compare RUBI & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RUBI

Rubico Inc. Common Stock

N/A

Current Price

$1.65

Market Cap

2.8M

ML Signal

N/A

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$1.75

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUBI
SHPH
Founded
N/A
2012
Country
Marshall Islands
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
3.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RUBI
SHPH
Price
$1.65
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.2M
363.0K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.63
$1.26
52 Week High
$200.70
$25.25

Technical Indicators

Market Signals
Indicator
RUBI
SHPH
Relative Strength Index (RSI) N/A 41.09
Support Level N/A $1.65
Resistance Level N/A $1.93
Average True Range (ATR) 0.00 0.21
MACD 0.00 0.09
Stochastic Oscillator 0.00 62.82

Price Performance

Historical Comparison
RUBI
SHPH

About RUBI Rubico Inc. Common Stock

Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: